Bristol-Myers Squibb’s acquisition of Celgene will unite two drugmakers battling for advantage in a crowded market for innovative cancer treatments, according to the Los
Angeles Times. Bristol makes an immunotherapy drug called Opdivo that accounts for roughly a quarter of its sales but that has trailed a rival medication from Merck. Celgene has been looking for a
follow-up for its blockbuster blood-cancer therapy Revlimid.
Read the whole story at Los Angeles Times »